lugoneseditorial.com.ar 的前十大競爭對手

medpharmres.com

medpharmres is owned by the university of medicine and pharmacy at ho chi minh city and published under open access arrangement. medpharmres publishes quarterly and covers all fields in medicine, public health, epidemiology, and pharmacy, including drug synthesis and delivery and health and medical education research, in an attempt to bridge the gaps between healthcare and clinical specialization. the journal’s publication criteria are based on the accuracy of the research methodology and high ethical standards.

attd.kenes.com

Contact Us for ATTD 2026 – The 19th International Conference on Advanced Technologies & Treatments for Diabetes, the leading international diabetes conference, taking place in Barcelona, Spain 11-14 March..

sanatorioargentino.com.ar

Conocé el calendario completo de actividades que tiene Sanatorio Argentino para cada mes del año. Eventos, Horarios, Lugares, todo en la Agenda 2017.

cecbuenosaires.com.ar

Espacios del Centro de Convenciones Buenos Aires - Centros de Convenciones más importantes de América Latina - Congresos - Convenciones

unlok-education.com

Discover the AD/PD™ education portal for HCPs specializing in Neurology. Sign up to gain exclusive access to valuable insights, resources and live events.

bsfit.com.ar

Banco de gimnasio ajustable con respaldo en 8 posiciones. Diseño plegable, resistente y cómodo. Ideal para entrenamientos completos. ¡Comprá en BSFit!

cvironline.org

How can I access CVIR? How do I submit my manuscript to CVIR? What types of manuscripts can I submit to CVIR?

pharmacia.pensoft.net

Cancer remains one of the leading causes of death globally and is expected to increase in incidence. The present investigation aimed to evaluate the anticancer efficacy of gemcitabine derivatives on MCF7, A549, and PC3 cell lines. Compounds Com. 10 and Com. 16 were the most potent, with IC₅₀ values of 9.45, 6.93, and 12.09 µM (Com. 10) and 12.23, 6.60, and 21.57 µM (Com. 16) for the three cell lines, showing a better response compared to the reference drug gemcitabine. Com. 9 and Com. 14 were also moderately active, preferentially on A549 and PC3. Com. 16 showed strong binding with the active residues as determined by molecular docking. Com. 16 bound to key cancer targets Vav1 (6NEW), ERK2 (4ZXT), and CYP3A4 (7LXL), with docking scores of −191.72, −187.66, and −221.08 kcal/mol, respectively. These interactions were electrostatic, hydrophobic, and π-type, similar to those induced by gemcitabine. Several other compounds also demonstrated good docking scores (−160 to −180 kcal/mol), and eight protein–ligand complexes emerged as leads. Moreover, ADME and physicochemical analyses of the top six active compounds indicated good drug-likeness and a favorable PK profile compared to gemcitabine.